GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
51.02
-1.35 (-2.58%)
At close: Nov 16, 2026, 4:00 PM EST
51.51
+0.49 (0.96%)
After-hours: Nov 16, 2026, 7:47 PM EST
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $123.10M in the quarter ending September 30, 2026, with 5.45% growth. This brings the company's total for the last twelve months to $460.78M, up 14.57% year-over-year. In the year 2025, GeneDx Holdings had annual revenue of $427.54M with 39.97% growth. That makes GeneDx Holdings the 11,733rd largest company in the world by revenue and 2,337th in the United States.
Revenue (ttm)
$460.78M
Revenue Growth
+14.57%
P/S Ratio
3.32
Revenue / Employee
$354,449
Employees
1,300
Market Cap
1.53B
Revenue by Segment
- GeneDx 423.09M 99.0%
- Fabric Genomics and Legacy Sema4 4.45M 1.0%
Fiscal year ended Dec 31, 2025 See the full GeneDx Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 427.54M | 122.09M | 39.97% |
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | 196.17M | 62.83M | 47.12% |
| Dec 31, 2018 | 133.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sotera Health Company | 1.23B |
| Myriad Genetics | 803.60M |
| NeoGenomics | 787.75M |
| OPKO Health | 654.10M |
| Veracyte | 581.78M |
| CareDx | 497.40M |
| Castle Biosciences | 377.13M |
| Fulgent Genetics | 330.28M |
WGS News
- 3 days ago - GeneDx price target lowered to $66 from $103 at Craig-Hallum - TheFly
- 5 days ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire
- 6 days ago - GeneDx price target lowered to $65 from $95 at Piper Sandler - TheFly
- 6 days ago - GeneDx price target lowered to $85 from $90 at BTIG - TheFly
- 6 days ago - GeneDx announces new research to be presented at NSGC Annual Conference - TheFly
- 6 days ago - GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients - Business Wire
- 7 days ago - GeneDx Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 7 days ago - GeneDx Holdings Earnings release: Q3 2026 - Filings